EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or “the Company”) (NASDAQ: EXEL) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Exelixis missed analyst consensus estimates with its Q2 revenue and also lowered its full-year 2026 revenue guidance.

The revenue shortfall came alongside an adjusted EPS beat of $0.91 per share. Investors sold on the top-line number. The Company attributed the reduced full-year outlook to a slower-than-expected ramp in its neuroendocrine-tumor business -- a franchise Exelixis had described to investors as a market-leading position for CABOMETYX in the oral second-line plus segment.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [e-mail]

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260816581958/en/

The Exelixis Stock at the time of publication of the news with a raise of +1,24 % to 51,24USD on Nasdaq stock exchange (15. August 2026, 02:00 Uhr).

Schreibe Deinen Kommentar